Small molecule company Cambrex has completed the expansion of a new research and development facility in Italy.
Cambrex Milan
The company’s new R&D laboratory, situated in Paullo, Milan, includes both chemistry and analytical development capabilities, with the installation of semi-automated glass lined reactors, as well as analytical instruments including multiple high and ultra-performance liquid chromatography, and gas chromatography systems.
The company has also installed a flow chemistry system to allow for continuous manufacturing development.
In addition, the company has also installed a 12,000 litre reactor into one of its cGMP manufacturing facilities as part of a $3 million investment to upgrade the efficiency of the plant, which manufactures intermediates and generic APIs.
“This investment is part of our ongoing strategy to ensure that the site can adapt to the growing and evolving needs of the generic API industry,” commented Aldo Magnini, managing director, Cambrex Milan. “Investing in key technologies such as continuous flow will allow us to look at new opportunities for the site to expand our portfolio of generic products, in a similar manner to the investment in highly potent API containment that we undertook in 2017, which allowed us to increase the number of new highly-potent oncology products in development.”